Corient Private Wealth LLC Sells 13,615 Shares of Sanofi $SNY

Corient Private Wealth LLC lessened its position in shares of Sanofi (NASDAQ:SNY) by 14.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,716 shares of the company’s stock after selling 13,615 shares during the quarter. Corient Private Wealth LLC’s holdings in Sanofi were worth $3,863,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of SNY. Raymond James Financial Inc. raised its position in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the period. Capital Research Global Investors bought a new position in Sanofi during the fourth quarter valued at $79,960,000. Morgan Stanley raised its stake in shares of Sanofi by 20.4% in the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after acquiring an additional 1,540,271 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Sanofi by 29.7% in the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after acquiring an additional 1,168,339 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Sanofi by 422.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock worth $50,165,000 after acquiring an additional 859,246 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of Sanofi stock opened at $42.95 on Friday. The company has a 50 day moving average price of $44.16 and a 200 day moving average price of $46.04. The firm has a market capitalization of $104.13 billion, a P/E ratio of 12.00, a PEG ratio of 1.03 and a beta of 0.34. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were paid a $2.4225 dividend. The ex-dividend date was Monday, May 4th. This represents a dividend yield of 559.0%. This is a boost from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Wall Street Analyst Weigh In

SNY has been the topic of a number of recent analyst reports. Citigroup reissued a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Morgan Stanley set a $52.00 price objective on Sanofi in a report on Friday, May 1st. Finally, Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.